Kedrion Biopharma, an international biopharmaceutical company with corporate headquarters in Tuscany, Italy, specializes in the production of plasma-derived therapies for rare diseases and conditions such as hemophilia and primary immunodeficiency. Kedrion Biopharma’s US headquarters are in Fort Lee, New Jersey with a global presence in about 100 countries.